Do I need an in-person exam for Mounjaro in Illinois?

Quick Answer: Yes, you can legally get GLP-1 weight loss medications like Wegovy, Ozempic, or Mounjaro through telehealth in most U.S. states. Because these medications aren’t controlled substances, federal law doesn’t require an in-person visit before prescribing. However, state-specific rules vary—some require initial in-person exams, while others permit completely virtual care from start to finish.

If you’re considering telehealth for weight management, understanding your state’s requirements can save time and help you access care safely and legally.

Understanding Federal Telehealth Rules for Weight Loss Medications

GLP-1 Medications Are Not Controlled Substances

Unlike Adderall or other stimulant medications regulated under the Ryan Haight Act, GLP-1 agonists (semaglutide and tirzepatide) are unscheduled drugs. This means:

• No federal law requires an in-person examination before prescribing them via telehealth
• Providers can establish a valid patient relationship through live video consultations
• Electronic prescriptions can be sent directly to your pharmacy after an online evaluation

The Ryan Haight Act’s in-person exam requirement applies exclusively to controlled substances. Since Wegovy, Ozempic, and Mounjaro fall outside this category, telehealth providers have more flexibility under federal regulations.

Current DEA Telehealth Flexibility (Through December 2025)

While not directly affecting GLP-1 prescriptions, it’s worth noting that the DEA has extended COVID-era telehealth flexibilities for controlled substances through December 31, 2025. This temporary measure allows providers to prescribe medications like buprenorphine and ADHD treatments via telehealth without initial in-person visits.

Though this extension doesn’t impact weight loss medications, it signals federal support for expanded telehealth access across healthcare categories.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

State-by-State Telehealth Requirements

While federal law permits telehealth prescribing of GLP-1 medications, state regulations create the real variation in how you can access these treatments online. Here’s what you need to know about key states:

States Requiring Initial In-Person Exams

Several states mandate at least one in-person visit before or shortly after starting telehealth weight loss treatment:

Arkansas maintains some of the nation’s strictest telehealth rules. Providers must conduct an initial face-to-face examination to establish a valid doctor-patient relationship before prescribing weight loss medications. Legislative proposals to ease these restrictions were under review in late 2025.

Georgia requires an initial in-person physical exam before telehealth prescribing can begin. A significant 2024 law change now allows nurse practitioners and physician assistants to prescribe Schedule II controlled substances with physician delegation—though this doesn’t eliminate the in-person requirement for obesity treatment.

Delaware mandates a physical examination in person before providers can prescribe weight loss medications via telehealth. After the initial visit, ongoing care can continue virtually.

Mississippi requires patients to be seen at least once in person for weight management therapy. The state is currently debating legislation to expand nurse practitioner independence, which could affect telehealth access in coming years.

New Jersey enforces particularly comprehensive initial requirements: a thorough physical exam, laboratory work, psychological screening, and documentation of diet/exercise attempts before prescribing any weight loss medication. Providers must also obtain detailed informed consent covering medication risks.

North Dakota expects a hands-on initial evaluation for weight loss treatment per state medical board guidance, though the state otherwise embraces telehealth broadly.

South Carolina mandates an initial in-person visit and requires periodic in-person evaluations during ongoing treatment.

Texas standard of care typically dictates an initial in-person exam, though telehealth follow-ups are permitted. Texas also requires nurse practitioners and physician assistants to operate under physician delegation agreements—they cannot practice independently.

Utah encourages (but doesn’t legally mandate) an initial in-person baseline evaluation, reflecting medical best practices rather than hard law.

Virginia has detailed Board of Medicine rules requiring an initial physical examination, laboratory work, and a personalized diet and exercise plan before any weight loss drug prescription. Follow-up visits must occur within 30 days of starting therapy.

States Allowing Fully Virtual Care

Many states permit weight loss medication prescribing entirely through telehealth without in-person requirements:

California explicitly allows telehealth exams as sufficient to establish care. Nurse practitioners can practice independently after gaining three years of experience, making virtual weight loss programs widely accessible.

Connecticut has permanent telehealth laws with no in-person mandate. The state does require providers to include behavioral counseling and diet/exercise plans as part of obesity treatment.

Florida doesn’t require physical exams to be conducted in person, but state law imposes specific conditions: patients must have BMI ≥30, and follow-up visits must occur at least every three months during treatment.

Illinois allows completely virtual care with no special in-person rules beyond standard of care. The state mandates electronic prescribing for all medications.

New York permits telehealth exams to suffice for establishing care. Nurse practitioners gained full independent practice authority in 2022 after accumulating required clinical hours.

Pennsylvania has no in-person mandate for GLP-1 prescriptions. Nurse practitioners still require physician collaboration agreements, though independent practice legislation has been pending.

Washington pioneered telehealth adoption and imposes no in-person requirements. The state’s My Health My Data Act (2023) adds privacy protections especially relevant for sensitive weight-loss information.

Who Can Prescribe Weight Loss Medications via Telehealth?

Physician Prescribing Authority

All states allow medical doctors (MDs) and doctors of osteopathy (DOs) to prescribe GLP-1 medications via telehealth, provided they hold an active license in the state where the patient is physically located during the consultation.

Nurse Practitioner and Physician Assistant Authority

Nurse practitioners (NPs) and physician assistants (PAs) can prescribe weight loss medications in every state, but their level of autonomy varies significantly:

Independent Practice States (34 states plus DC as of 2025): NPs can prescribe without physician oversight after meeting experience requirements. These include California, Washington, New York, Arizona, Connecticut, Delaware, North Dakota, Utah, and Virginia.

Collaborative Practice States: NPs and PAs must maintain formal agreements or protocols with supervising physicians. Examples include Arkansas, Florida, Illinois, Mississippi, New Jersey, Pennsylvania, South Carolina, and Texas.

Recent Expansions: Georgia’s 2024 law now permits NPs and PAs to prescribe Schedule II controlled substances under physician delegation (previously prohibited). Indiana and Michigan enacted full practice authority for NPs in 2024, joining the majority of states.

At Klarity Health, we work exclusively with licensed, credentialed providers who operate within their state’s scope of practice—whether MDs, DOs, NPs, or PAs. This ensures you receive legally compliant, high-quality care regardless of which type of provider conducts your consultation.

Clinical Eligibility: Who Qualifies for Telehealth Weight Loss Treatment?

Standard Medical Criteria

Reputable telehealth providers screen carefully before prescribing GLP-1 medications. You generally must meet these criteria:

BMI Requirements:

• BMI ≥30 (obesity), OR
• BMI ≥27 with weight-related comorbidities (type 2 diabetes, hypertension, dyslipidemia, sleep apnea)

Lifestyle Modification Attempts: Documentation that you’ve tried diet and exercise modifications (unless medically inadvisable)

Medical History Review: Comprehensive evaluation of current medications, allergies, and chronic conditions

Lab Work: Many states and clinical best practices require recent laboratory results (metabolic panel, A1C, lipid panel, thyroid function)

Common Contraindications

Telehealth providers will screen for conditions that disqualify patients from GLP-1 therapy:

• Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)—all GLP-1s carry an FDA boxed warning for these conditions
• Current pregnancy or plans to become pregnant (must discontinue 2 months before conception)
• Active gallbladder disease or history of severe pancreatitis
• Severe gastrointestinal disorders like gastroparesis
• History of eating disorders or body dysmorphia (relative contraindication requiring psychiatric clearance)

What to Expect During Your Telehealth Evaluation

A legitimate telehealth weight loss consultation will include:

Detailed Medical Questionnaire: Comprehensive health history, previous weight loss attempts, current medications, and lifestyle factors

Live Video Consultation: Discussion with a licensed provider (typically 15-30 minutes) covering your goals, medical appropriateness, risks/benefits, and treatment expectations

Informed Consent: Written documentation of medication risks (GI side effects, gallstone formation, injection technique) and alternatives to medication

Treatment Plan: Not just a prescription—expect lifestyle recommendations, dietary guidance, and scheduled follow-ups

Verification of Measurements: Self-reported height and weight with possible photo verification or scale readings

Many states specifically mandate certain elements. For instance, Florida requires documentation of BMI calculation, Connecticut mandates behavioral counseling inclusion, and New Jersey requires extensive psychological screening.

Medication Overview: What Telehealth Can Prescribe

Wegovy (Semaglutide 2.4mg)

FDA Status: Approved specifically for chronic weight management (June 2021)

Typical Dosing: Weekly self-injection, starting at 0.25mg and titrating up to 2.4mg over 16-20 weeks

Supply: Initial prescriptions typically cover 4 weeks; maintenance prescriptions may be 30-90 days

Telehealth Considerations: Fully legal to prescribe via telehealth in all states (subject to state-specific evaluation requirements). No compounding permitted since FDA shortage declaration ended in 2024.

Ozempic (Semaglutide 0.5-1mg)

FDA Status: Approved for type 2 diabetes management; commonly prescribed off-label for weight loss

Typical Dosing: Weekly injection, 0.25mg-1mg

Telehealth Considerations: Legal to prescribe via telehealth for off-label weight loss use, but providers must document medical rationale and obtain informed consent about off-label status. Same active ingredient as Wegovy—patients should never use both simultaneously.

Mounjaro (Tirzepatide) / Zepbound

FDA Status: Mounjaro approved for diabetes (May 2022); Zepbound (tirzepatide 15mg) approved for obesity (November 2023)

Typical Dosing: Weekly injection with dose escalation

Telehealth Considerations: Prescribable via telehealth when patients meet clinical criteria. When prescribed for weight loss in patients without diabetes, off-label documentation may be needed unless using the Zepbound formulation.

Important Prescribing Notes

None of these medications are controlled substances, eliminating federal barriers to telehealth prescribing. All require:

• Valid patient-provider relationship (established via live video in most cases)
• Electronic prescription to licensed pharmacy
• Patient education on self-injection technique
• Regular monitoring and follow-up

Compounded versions: The FDA ended emergency allowances for compounded semaglutide in May 2025. Legitimate telehealth providers now prescribe only FDA-approved, manufacturer-supplied medications dispensed through licensed pharmacies.

State-Specific Follow-Up and Monitoring Requirements

Beyond initial prescribing, several states mandate ongoing monitoring:

Florida: Requires follow-up visits at least every three months during treatment

Virginia: Mandates a check-in approximately 30 days after starting therapy, then ongoing periodic evaluations

Connecticut: Requires continued behavioral counseling and diet/exercise plan documentation

New Jersey: Extensive ongoing monitoring including periodic lab work and psychological assessment

Even in states without legal mandates, clinical best practice involves:

• 1-month follow-up after starting medication (assess tolerance, adjust dose)
• Every 2-3 months thereafter (monitor weight loss progress, side effects, vital signs)
• Periodic lab work (every 3-6 months: metabolic panel, A1C if diabetic, lipid panel)
• Reassessment of treatment goals and medication continuation at 6-12 months

Klarity Health structures follow-up care to exceed minimum state requirements, ensuring patient safety and optimal outcomes through regular video check-ins and clinical monitoring.

Red Flags: How to Identify Illegitimate Telehealth Services

The popularity of GLP-1 medications has attracted questionable providers. Protect yourself by avoiding services that:

Guarantee Prescriptions Without Evaluation

Legitimate providers assess whether you’re medically appropriate for treatment. Services promising ‘instant approval’ or ‘guaranteed prescriptions’ likely skip necessary medical screening.

Offer Compounded or International Versions

Since the FDA banned routine compounding of semaglutide in May 2025, offers of ‘cheaper compounded Wegovy’ or medications shipped from overseas should raise immediate concerns about safety and legality.

Skip Follow-Up Care

Weight loss medication requires ongoing monitoring. One-and-done prescriptions without scheduled follow-ups indicate substandard care that could miss serious side effects.

Lack Transparent Licensing Information

You should easily verify your provider’s name, credentials, and state license. Services that won’t disclose who will prescribe your medication or where they’re licensed are concerning.

Don’t Discuss Risks and Alternatives

Proper informed consent involves explaining common side effects (nausea, vomiting, diarrhea, constipation), serious risks (pancreatitis, gallbladder disease), contraindications, and non-medication alternatives. Providers who rush through or skip this discussion aren’t meeting professional standards.

Use High-Pressure Sales Tactics

Healthcare decisions shouldn’t feel like buying a car. Legitimate providers give you time to consider treatment, ask questions, and make informed choices without pressure.

Insurance Coverage and Cost Considerations

Insurance Coverage for Telehealth Weight Loss Treatment

Coverage varies significantly by insurer and plan:

Medicare: Covers obesity counseling via telehealth but generally doesn’t cover GLP-1 medications prescribed solely for weight loss (coverage exists for diabetes indications)

Medicaid: State-dependent; some states cover GLP-1s for obesity, others don’t

Private Insurance: Increasingly covering GLP-1s for weight loss, particularly when BMI criteria and prior authorization requirements are met. Many plans now cover telehealth consultations at parity with in-person visits.

Self-Pay Options

For patients paying out-of-pocket:

Medication Costs: Retail prices for brand-name GLP-1s range $900-$1,500/month without insurance. Manufacturer savings programs, patient assistance programs, and pharmacy discount cards can reduce costs.

Consultation Fees: Telehealth visit fees typically range $50-$200 for initial consultations and $30-$100 for follow-ups.

Klarity Health accepts both insurance and offers transparent cash-pay pricing, making weight loss treatment accessible regardless of coverage status. Our team helps navigate prior authorizations and identifies cost-saving programs when insurance doesn’t cover medications.

The Future of Telehealth Weight Loss Treatment

Regulatory Outlook for 2026 and Beyond

Several trends suggest expanding telehealth access:

Federal Legislation: The TREATS Act, reintroduced in October 2025, could permanently allow telehealth prescribing of controlled substances without in-person exams. While not directly affecting GLP-1s, its passage would signal Congressional endorsement of prescriptive telehealth.

DEA Rules: The temporary telehealth flexibilities for controlled substances expire December 31, 2025, but signals point toward additional extensions or new permanent regulations rather than sudden restrictions.

State Evolution: At least five states will consider bills in 2026 to expand nurse practitioner independence and streamline telehealth requirements. The trend is toward fewer barriers, not more.

Interstate Compacts: More states joining licensure compacts make it easier for telehealth providers to offer services across state lines legally.

Emerging Treatment Options

New obesity medications in the pipeline will expand telehealth treatment options:

• Oral GLP-1 formulations (eliminating injection requirements)
• Combination therapies targeting multiple metabolic pathways
• Next-generation incretin mimetics with improved efficacy and tolerability

As these treatments become available, telehealth will remain the most accessible delivery model for most patients.

How Klarity Health Supports Your Weight Loss Journey

At Klarity Health, we’ve built our telehealth weight management program around safety, accessibility, and results:

Licensed Providers in Your State: Our medical team includes board-certified physicians, experienced nurse practitioners, and physician assistants licensed in 17+ states and growing.

Comprehensive Evaluations: Every patient receives a thorough medical assessment—we don’t cut corners to speed up prescriptions.

Transparent Pricing: Clear upfront costs with no hidden fees. We accept major insurance plans and offer affordable self-pay options.

Flexible Access: Video consultations that fit your schedule, with evening and weekend availability. No need to take time off work or arrange childcare for in-person visits.

Ongoing Support: Regular follow-ups, medication adjustments, lifestyle coaching, and 24/7 access to care coordination help—not just a prescription and goodbye.

Evidence-Based Care: Our protocols align with current clinical guidelines and state regulations, ensuring you receive care that’s both effective and legally compliant.

Whether you’re in California where telehealth is fully embraced or Texas where initial in-person exams are standard practice, Klarity works within your state’s requirements to provide the highest quality weight management care.

Frequently Asked Questions

Do I need to have tried other weight loss methods before getting prescribed via telehealth?

Most providers will ask about previous diet and exercise attempts. This isn’t necessarily a barrier—rather, it helps determine the most appropriate treatment. If medical conditions prevent lifestyle modifications, providers can document this.

Can I use telehealth if I live in a rural area?

Absolutely. Telehealth specifically benefits patients in underserved areas with limited access to obesity medicine specialists. As long as you have internet access for video consultations, geographic location within your state doesn’t matter.

What happens if I move to another state during treatment?

Your provider must be licensed in the state where you’re physically located. If you move, you’ll need to transfer care to a provider licensed in your new state. Klarity Health operates in multiple states and can often facilitate seamless transitions.

Are telehealth prescriptions filled at regular pharmacies?

Yes. Your electronic prescription goes to your chosen pharmacy (local or mail-order), where you pick up FDA-approved, manufacturer-supplied medication—exactly the same as if prescribed in person.

How long does it take to get started?

After scheduling a consultation (often available within days), you’ll complete intake paperwork, have a video visit with a provider, and if approved, receive your prescription the same day. Medication availability at your pharmacy may vary based on current supply.

What if I experience side effects?

Contact your provider immediately. Klarity offers ongoing support between scheduled visits—you’re never left wondering whether symptoms are normal or concerning. Dose adjustments or medication changes can be made as needed.

Take the First Step Toward Your Weight Loss Goals

Telehealth has transformed access to evidence-based weight management care. Whether you’re struggling with obesity-related health conditions or simply haven’t achieved results through diet and exercise alone, GLP-1 medications prescribed through telehealth offer a convenient, effective option.

Understanding your state’s specific requirements helps set realistic expectations, but the core message is encouraging: most Americans can legally access these treatments through virtual care, often with fewer barriers than traditional in-person weight loss clinics.

Ready to explore whether telehealth weight loss treatment is right for you? Klarity Health’s experienced medical team is here to help. Our streamlined process respects your time while ensuring thorough, personalized care that meets the highest medical and regulatory standards.

Schedule your confidential consultation today and discover how accessible, affordable weight management care can be when delivered through a telehealth platform that prioritizes both your health and convenience.

Research Currency and Citations

Verified as of: December 17, 2025

This article draws on current federal regulations, state medical board guidance, and recent legislative changes affecting telehealth prescribing. The regulatory landscape continues to evolve—DEA’s COVID-era telehealth flexibilities remain in effect through December 31, 2025, with extensions anticipated for 2026.

Top Citations

1. DEA and HHS Extend Telemedicine Flexibilities through 2025 – U.S. Drug Enforcement Administration, November 15, 2024. Official announcement confirming extension of telehealth prescribing flexibilities for controlled substances through December 31, 2025. www.dea.gov

2. ‘COVID-era telehealth prescribing extended’ – Axios, November 18, 2024. News coverage of DEA’s third extension of pandemic-era telehealth rules, providing context on federal regulatory direction. www.axios.com

3. ‘The Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ – Goodwin Procter LLP, March 27, 2024. Comprehensive legal analysis of state-specific requirements for prescribing GLP-1 medications, including detailed coverage of Florida, New Jersey, and Virginia regulations. www.goodwinlaw.com

4. ‘Hims to cut 4% of workforce amid ban on weight-loss drug copies’ – Reuters, May 30, 2025. Reporting on FDA’s decision to end emergency compounding allowances for semaglutide, significantly impacting telehealth business models. www.reuters.com

5. ‘Know Your State’s Laws Around Semaglutide Prescribing’ – Nextech Blog, April 11, 2025. State-by-state breakdown of telehealth prescribing requirements, in-person exam mandates, and provider authority variations. www.nextech.com

Additional sources consulted include state medical board websites, Texas Medical Board prescribing guidelines, nurse practitioner scope of practice databases, and federal telehealth policy analyses from healthcare law firms. State laws are constantly evolving; readers should verify current requirements in their specific state at the time of seeking care.

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid